October-December
· Total revenue of
· Adjusted EBITA[1,2] was
· Earnings per share (EPS) of
· Net debt[1] of
· Elocta® sales were
· Sales for Gamifant® amounted to
· Acquisition of Dova Pharmaceuticals[TM] was completed
January-December
· Total revenue of
· Adjusted EBITA[1,2] was
· Earnings per share (EPS) of
· Elocta sales were
· Gamifant sales amounted to
· Synagis sales for the period 23 Jan - 31 Dec were
· Kineret sales were
Outlook 2020[4]
· Revenue for the full-year 2020 is expected to be in the range of
· EBITA is expected to be in the range of
Financial review
[][][][][][][][][][]
Q4 Q4 Full Full-year
-year
Amounts in SEK M 2019 2018 Change 2019 2018 Change
Total revenue 4,890 2,571 90% 14,248 9,139 56%
Gross profit 3,833 1,894 102% 10,913 6,723 62%
Gross margin[1] 78% 74% 77% 74%
EBITA[1] 2,288 916 150% 5,933 3,571 66%
EBITA adjusted[1,2] 2,380 916 160% 6,145 3,571 72%
EBITA margin[1] 47% 36% 42% 39%
EBITA margin 49% 36% 43% 39%
adjusted[1,2]
EBIT (operating 1,874 802 134% 4,533 3,122 45%
profit)
Profit for the 1,360 595 129% 3,304 2,418 37%
period
Earnings per share, 4.62 2.20 110% 11.29 8.97 26%
SEK
Earnings per share, 4.90 2.20 122% 11.89 8.97 33%
SEK adjusted[1,2,3]
[1]Alternative
Performance
Measures (APMs).
[2]EBITA full-year
2019 excluding non
-recurring items;
transaction costs
related to the
acquisition of Dova
in Q4 of
restructuring costs
of
and gain from
divestment of
SOBI005 in Q1 of
[3]EPS full-year
2019 excluding
impairment of
intangible assets
of
to restructuring in
Q2.
[4]At current
exchange rates
"The year ended on a very strong note. Total revenue for full-year 2019 was
Telephone conference:
Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the Q4 and FY results, today at
The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.
To participate in the telephone conference, please call:
SE: +46 8 505 583 55
US: +1 646 722 4902
Click here to go to the live webcast. (https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=&eventid=2172532&sessionid=1&key=64FA3B636320F32DF4CA98068F533D74®Tag=&sourcepage=register)
After the live event the webcast will be available on-demand via the same URL.
---
About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,300 people across
For more information please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
+ 46 708 734 095
linda.holmstrom@sobi.com
This information is information that
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-report-for-the-fourth-quarter-and-full-year-2019,c3033895
https://mb.cision.com/Main/14266/3033895/1192758.pdf
(c) 2020 Cision. All rights reserved., source